New York • The following is a list of initial public offerings planned for the coming week. Sources include Renaissance Capital, Greenwich, CT (www.renaissancecapital.com) and SEC filings.
Week of June 30:
Ambrx Inc. - La Jolla, Calif., 5.4 million shares, priced $12 to $14, managed by Stifel and Wells Fargo. Proposed Nasdaq symbol AMBX. Business: Clinical stage biotech developing optimized protein therapeutics known as bio-conjugates.
GlobeImmune Inc. - Louisville, Colo., 1.6 million shares, priced $15 to $17, managed by Aegis Capital. Proposed Nasdaq symbol GBIM. Business: Developing therapeutic drugs for pancreatic cancer and hepatitis B and C. Previously withdrew in October 2013.